Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Important Update

HHS Announces State/territory-coordinated Distribution System for Monoclonal Antibody Therapeutics

September 13, 2021

Monoclonal Antibody Therapeutic Updates

The COVID-19 pandemic is rapidly evolving, and new updates are issued frequently. To view a full list of HHS/ASPR’s updates related to COVID-19 monoclonal antibody therapeutics, please see our full list of updates.


The increased incidence of the Delta variant of SARS-CoV-2 has caused a substantial surge in the utilization of monoclonal antibody (mAb) drugs, particularly in areas of the country with low vaccination rates. HHS is committed to helping ensure consistent availability of these critical drugs for current and future patients in all geographic areas of the country. As such, we have updated the distribution process for mAbs.

On Monday, September 13, HHS transitioned from a direct ordering process to a state/territory-coordinated distribution system similar to that used for the distribution of mAbs from November 2020 – February 2021.

State and territorial health departments know best where product is needed in their areas. Transitioning to a state/territory-coordinated distribution system gives health departments maximum flexibility to get these critical drugs where they are needed most.

HHS will determine the weekly amount of mAb products each state and territory receives based on COVID-19 case burden and mAb utilization. State and territorial health departments will subsequently identify which sites in their respective jurisdictions receive product as well as the amount each site receives. 

As of Monday, September 13, 2021:

    • Administration sites no longer order directly from AmerisourceBergen.
    • Weekly distribution amounts for each state/territory will be determined by HHS based on weekly reports of new COVID-19 cases and hospitalizations in addition to data on inventories and use submitted to the federal government.
    • State/Territorial Health Departments will determine where product goes in their jurisdictions.








State/Territory Distributions for Week of September 13, 2021

HHS will continue to monitor product utilization rates, COVID-19 case burden, and overall availability of monoclonal antibody therapeutics to determine when a shift back to the normal direct ordering process may be possible.

State/Territory Name Bamlanivimab/etesevimab
Doses
REGN-COV
Doses
Alaska 60470
Alabama 8107,220
Arkansas 3703,260
American Samoa 020
Arizona 1801,620
California 5204,610
Colorado 100860
Connecticut 40290
District of Columbia 30180
Delaware 20180
Florida 3,10027,850
Georgia 1,0008,920
Guam 0120
Hawaii 70610
Iowa 1401,190
Idaho 110970
Illinois 2802,490
Indiana 3102,710
Kansas 110940
Kentucky 5004,460
Louisiana 8507,650
Massachusetts 70570
Maryland 110910
Maine 30270
Michigan 1901,690
Minnesota 1301,090
Missouri 2301,990
Commonwealth of the Northern
Mariana Islands
010
Mississippi 9608,550
Montana 80720
North Carolina 6505,850
North Dakota 40340
Nebraska 80680
New Hampshire 40330
New Jersey 2301,980
New Mexico 80650
Nevada 100820
New York 4904,410
Ohio 3703,250
Oklahoma 3202,840
Oregon 1401,240
Pennsylvania 2201,970
Puerto Rico 40270
Rhode Island 30250
South Carolina 4504,010
South Dakota 50380
Tennessee 7806,940
Texas 2,37021,270
Utah 1401,190
Virginia 1601,370
Virgin Islands 030
Vermont 20120
Washington 1301,160
Wisconsin 1401,210
West Virginia 1601,440
Wyoming 50360
Indian Health Service 100900
Veteran's Health Administration 100900
Totals 17,880 158,580


Monoclonal Antibody Therapeutic Updates

The COVID-19 pandemic is rapidly evolving, and new updates are issued frequently. To view a full list of HHS/ASPR’s updates related to COVID-19 monoclonal antibody therapeutics, please see our full list of updates.


  • This page last reviewed: September 15, 2021